VistaGen Therapeutics Inc (VTGN)

Name: VistaGen Therapeutics Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$303K

Net Income

-$18.9M

Operating Margin

-6,450.8%

Free Cash Flow

-$42.3M

Debt / Assets

16.5%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for VistaGen Therapeutics Inc (VTGN).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2024-12-31
Revenue	303,000	258,000	244,000	234,000
Cost of Revenue	189,000	0	169,000	161,000
Gross Profit	114,000	258,000	75,000	73,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	5,491,000	4,396,000	4,370,000	4,049,000
Operating Expenses	19,660,000	20,311,000	15,879,000	15,354,000
Operating Income	-19,546,000	-20,053,000	-15,804,000	-15,120,000
Interest Expense	0	0	0	0
Income Before Tax	-18,899,000	-19,417,000	-15,095,000	-14,089,000
Income Tax Expense	0	0	0	0
Net Income	-18,899,000	-19,417,000	-15,095,000	-14,089,000
Per Share
EPS	-0.45	-0.54	-0.47	-0.46
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for VistaGen Therapeutics Inc (VTGN).
Income Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Revenue	486,000	1,064,000	-227,000	1,108,900	1,089,500
Cost of Revenue	0	0	0	815,200	0
Gross Profit	486,000	1,064,000	-227,000	293,700	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	17,084,000	14,063,000	14,664,000	13,248,000	6,547,000
Operating Expenses	56,459,000	34,085,000	59,041,000	48,655,800	19,023,400
Operating Income	-55,973,000	-33,021,000	-59,268,000	-47,778,900	-17,933,800
Interest Expense	0	0	23,000	232,000	13,000
Income Before Tax	-51,411,000	-29,358,000	-59,242,000	-47,759,000	-17,931,600
Income Tax Expense	7,000	4,000	6,000	3,400	2,600
Net Income	-51,418,000	-29,362,000	-59,248,000	-47,762,400	-17,934,200
Per Share
EPS	-1.67	-1.52	-8.51	-7.24	-0.21
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for VistaGen Therapeutics Inc (VTGN).
Balance Sheet (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Assets
Cash and Cash Equivalents	67,131,000	119,166,000	16,637,600	68,135,300
Short Term Investments	13,351,000	0	0	0
Net Receivables	0	0	802,700	337,900
Inventory	0	0	-735,600	2,453,000
Total Current Assets	82,076,000	120,672,000	17,507,400	70,998,000
Property Plant Equipment	1,811,000	2,255,000	2,767,600	3,076,300
Goodwill and Intangibles	0	0	0	0
Total Assets	84,341,000	123,653,000	21,089,200	74,643,400
Liabilities
Account Payables	653,000	1,547,000	2,473,100	2,758,600
Short Term Debt	561,000	1,100,000	592,600	433,300
Total Current Liabilities	12,612,000	5,123,000	4,567,400	5,765,100
Long Term Debt	948,000	1,570,000	2,127,200	2,605,400
Total Liabilities	13,951,000	9,367,000	9,009,200	9,928,100
Shareholders Equity
Retained Earnings	-407,632,000	-356,214,000	-326,851,700	-267,604,000
Total Shareholders Equity	70,390,000	114,286,000	12,080,000	64,715,300

Balance sheet annual history for VistaGen Therapeutics Inc (VTGN).
Balance Sheet (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Assets
Cash and Cash Equivalents	67,131,000	119,166,000	16,637,600	68,135,300	103,108,300
Short Term Investments	13,351,000	0	0	0	0
Net Receivables	0	0	802,700	337,900	40,600
Inventory	0	0	-735,600	2,453,000	0
Total Current Assets	82,076,000	120,672,000	17,507,400	70,998,000	104,117,500
Property Plant Equipment	1,811,000	2,255,000	2,767,600	3,076,300	3,587,000
Goodwill and Intangibles	0	0	0	0	0
Total Assets	84,341,000	123,653,000	21,089,200	74,643,400	108,281,300
Liabilities
Account Payables	653,000	1,547,000	2,473,100	2,758,600	838,300
Short Term Debt	561,000	1,100,000	592,600	433,300	367,800
Total Current Liabilities	12,612,000	5,123,000	4,567,400	5,765,100	4,189,000
Long Term Debt	948,000	1,570,000	2,127,200	2,605,400	3,350,800
Total Liabilities	13,951,000	9,367,000	9,009,200	9,928,100	16,302,800
Shareholders Equity
Retained Earnings	-407,632,000	-356,214,000	-326,851,700	-267,604,000	-219,841,600
Total Shareholders Equity	70,390,000	114,286,000	12,080,000	64,715,300	91,978,500

Cash flow quarterly history for VistaGen Therapeutics Inc (VTGN).
Cash Flow Statement (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Activities
Net Income	-51,418,000	-29,362,000	-59,247,700	-47,762,400
Depreciation & Amortization	635,000	568,000	509,800	711,100
Stock Based Compensation	4,315,000	2,182,000	3,336,000	3,480,700
Change in Working Capital	4,760,000	793,000	2,028,200	-1,917,900
Operating Cash Flow	-42,097,000	-25,813,000	-49,715,100	-45,256,500
Investing Activities
Capital Expenditure	-191,000	-61,000	-212,000	-200,400
Investments	-191,000	-61,000	-212,000	-200,400
Investing Cash Flow	-13,148,000	-61,000	-740,300	-200,400
Financing Activities
Debt Repayment	0	-985,000	-1,500	-3,000
Common Stock Issued/Repurchased	3,009,000	129,379,000	-180,300	949,379,500
Dividends Paid	0	0	0	-945,100,000
Financing Cash Flow	3,210,000	128,402,000	-1,042,300	10,483,900
Summary
Free Cash Flow	-42,288,000	-25,874,000	-49,927,100	-45,456,900
Net Change in Cash	-52,035,000	102,528,000	-51,497,701	-34,973,000

Cash flow annual history for VistaGen Therapeutics Inc (VTGN).
Cash Flow Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Operating Activities
Net Income	-51,418,000	-29,362,000	-59,247,700	-47,762,400	-17,934,200
Depreciation & Amortization	635,000	568,000	509,800	711,100	117,600
Stock Based Compensation	4,315,000	2,182,000	3,336,000	3,480,700	2,306,100
Change in Working Capital	4,760,000	793,000	2,028,200	-1,917,900	3,437,000
Operating Cash Flow	-42,097,000	-25,813,000	-49,715,100	-45,256,500	-12,073,500
Investing Activities
Capital Expenditure	-191,000	-61,000	-212,000	-200,400	-275,400
Investments	-191,000	-61,000	-212,000	-200,400	-275,400
Investing Cash Flow	-13,148,000	-61,000	-740,300	-200,400	-275,400
Financing Activities
Debt Repayment	0	-985,000	-1,500	-3,000	-606,400
Common Stock Issued/Repurchased	3,009,000	129,379,000	-180,300	949,379,500	109,474,600
Dividends Paid	0	0	0	-945,100,000	0
Financing Cash Flow	3,210,000	128,402,000	-1,042,300	10,483,900	114,102,100
Summary
Free Cash Flow	-42,288,000	-25,874,000	-49,927,100	-45,456,900	-12,348,900
Net Change in Cash	-52,035,000	102,528,000	-51,497,701	-34,973,000	101,753,200